About     Clinical Trials

Our main focus is to ensure that your condition is treated with the most current evidence based approach. We are actively involved in clinical trials which help us stay at the forefront of our field. We are the first and only retinal private practice in the state of Oklahoma as part of the NIH/NEI sponsored Diabetic Retinopathy Clinical Research Network. Our referral ophthalmologists and optometrists are informed about our ongoing trials and send potentially eligible patients for screening visits.

Current On-going Clinical Trials.

NIH/NEI Sponsored Diabetic Retinopathy Clinical Research Network - DRCR.net - Dedicated to multicenter clinical research of diabetic retinopathy, macular edema and associated disorders

Protocol T - Comparative Effectiveness Study of Aflibercept, Bevacizumab and Ranibizumab for:

  • Recruitment Completed.
  • Diabetic Macular Edema.
  • Major Eligibility Criteria:

  • • Age ≥18 years.
    • Type 1 or type 2 diabetes.
    • Central-involved DME in study eye (OCT CSF ≥250 µm on Zeiss Stratus or the equivalent on spectral domain OCT based on gender specific cutoffs) within eight days of randomization.
    • Visual acuity letter score in study eye ≤ 78 and ≥24 (approximate Snellen equivalent 20/32 to 20/320) within eight days of randomization.
    • No history of an anti-VEGF treatment for DME in the past 12 months in the study eye and no history of any other treatment for DME in the study eye at any time in the past four months (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids).
    • No history of major ocular surgery in the study eye within prior four months or anticipated within the next six months following randomization.
    Back To Top

    Protocol V - Treatment for CI-DME in Eyes With Very Good VA Study

  • Currently Recruiting.
  • Diabetic Macular Edema.
  • Major Eligibility Criteria:

  • Ages Eligible for Study: 18 Years and older
    Genders Eligible for Study: Both
    Accepts Healthy Volunteers: No

    Brief Inclusion Criteria:
    1.Age >= 18 years
    2.Diagnosis of diabetes mellitus (type 1 or type 2)
    Meets all of the following ocular criteria in at least the one eye:
    1.Best corrected E-ETDRS visual acuity letter score ≥ 79 (approximate Snellen equivalent 20/25 or better) at two consecutive visits within 1 to 28 days.
    2.On clinical exam, definite retinal thickening due to DME involving the center of the macula.
    3.Diabetic macular edema confirmed on OCT (equivalent to CSF thickness on OCT ≥250 microns on Zeiss Stratus or gender-specific spectral domain OCT equivalent) at two consecutive visits within 1 to 28 days.
    Back To Top

    ORBIT - Ocriplasmin Research to Better Inform Treatment

  • Recruitment Completed.
  • Phase 4 multicenter, observational, phase 4 study to assess clinical outcomes and safety of Jetrea (Ocriplasmin) administered in a real world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites.
  • Major Eligibility Criteria:
  • •Adults 18 years or older diagnosed with symptomatic VMA treated with JETREA ® at the physician's discretion in a manner consistent with the product label.
    Back To Top